Predictive value of the clinically and scintigraphically important bone lesions in hormone-refractory prostate cancer (HRPC).
Zafeirakis
Athanasios
A
Limouris
Georgios S
GS
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy; D019008:Drug Resistance, Neoplasm; D006728:Hormones / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008297:Male; D008495:Medical Oncology / Q000379:methods; D011237:Predictive Value of Tests; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D006728:Hormones